Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ADI-001 for the treatment of refractory systemic lupus erythematosus (SLE) with extrarenal involvement.
The Company is evaluating ADI-001 across six autoimmune indications. Patient enrollment is ongoing in the Phase 1 study of ADI-001 for the treatment of lupus nephritis (LN). Patient enrollment in SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy, and stiff person syndrome (SPS) is expected to be initiated in the first quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.